Functional expression of sinusoidal and canalicular hepatic drug transporters in the differentiated human hepatoma HepaRG cell line

被引:136
作者
Le Vee, M
Jigorel, E
Glaise, D
Gripon, P
Guguen-Guillouzo, C
Fardel, O
机构
[1] INSERM, U620, Fac Pharm, F-35043 Rennes, France
[2] INSERM, U522, Fac Med, F-35043 Rennes, France
[3] CHU, Dept HITC, Rennes, France
关键词
drug transporter; hepatocytes; HepaRG cells; hepatoma; detoxification;
D O I
10.1016/j.ejps.2006.01.004
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Functional expression of both sinusoidal and canalicular hepatic drug transporters was investigated in the highly differentiated human hepatoma HepaRG cell line and also, for comparison, in primary human hepatocytes and in the hepatoma HepG2 cell line. Using RT-qPCR assays, differentiated HepaRG cells were found to display a pattern of transporter expression close to that found in primary human hepatocytes, i.e. they exhibit substantial mRNA levels of the influx transporters OCT1, OATP-B, OATP-C and NTCP, and of the secretion transporters MRP2, MRP3, BSEP and P-glycoprotein. By contrast, expression of influx transporters was not present or very weak in HepG2 cells. Drug transport assays allowed to detect functional activities of OCT1, OATPs/OAT2, NTCP, MRPs and P-glycoprotein in differentiated HepaRG cells as in primary human hepatocytes whereas HepG2 cells only showed notable MRP and P-glycoprotein activities. in addition, expression of canalicular transporters in HepaRG cells was found to be up-regulated by known inducers of transporters such as rifampicin, phenobarbital and chenodeoxycholate acting on P-glycoprotein, MRP2 and BSEP, respectively HepaRG cells thus exhibit functional expression of both sinusoidal and canalicular drug transporters and have retained regulatory pathways controlling transporter levels. These data, associated with the known high expression of drug metabolizing enzymes in HepaRG cells, highlight the interest of such hepatoma cells for analysing hepatic drug detoxification pathways. (c) 2006 Elsevier B.V. All rights reserved.
引用
收藏
页码:109 / 117
页数:9
相关论文
共 43 条
[1]   Human bile salt export pump promoter is transactivated by the farnesoid X receptor/bile acid receptor [J].
Ananthanarayanan, M ;
Balasubramanian, N ;
Makishima, M ;
Mangelsdorf, DJ ;
Suchy, FJ .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2001, 276 (31) :28857-28865
[2]   Expression of cytochromes P450, conjugating enzymes and nuclear receptors in human hepatoma HepaRG cells [J].
Aninat, C ;
Piton, A ;
Glaise, D ;
Le Charpentier, T ;
Langouët, S ;
Morel, F ;
Guguen-Guillouzo, C ;
Guillouzo, A .
DRUG METABOLISM AND DISPOSITION, 2006, 34 (01) :75-83
[3]   The bile salt export pump: molecular properties, function and regulation [J].
Arrese, M ;
Ananthanarayanan, M .
PFLUGERS ARCHIV-EUROPEAN JOURNAL OF PHYSIOLOGY, 2004, 449 (02) :123-131
[4]  
BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3
[5]   Inhibition of human organic anion transporting polypeptide OATP 1B1 as a mechanism of drug-induced hyperbilirubinemia [J].
Campbell, SD ;
de Morais, SM ;
Xu, JHJ .
CHEMICO-BIOLOGICAL INTERACTIONS, 2004, 150 (02) :179-187
[6]   Differential regulation of multidrug resistance-associated protein 2 (MRP2) and cytochrornes P4502B1/2 and 3A1/2 in phenobarbital-treated hepatocytes [J].
Courtois, A ;
Payen, L ;
Le Ferrec, E ;
Scheffer, GL ;
Trinquart, Y ;
Guillouzo, A ;
Fardel, O .
BIOCHEMICAL PHARMACOLOGY, 2002, 63 (02) :333-341
[7]   The amino acid residues asparagine 354 and isoleucine 372 of human farnesoid X receptor confer the receptor with high sensitivity to chenodeoxycholate. [J].
Cui, J ;
Heard, TS ;
Yu, JH ;
Lo, JL ;
Huang, L ;
Li, Y ;
Schaeffer, JM ;
Wright, SD .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2002, 277 (29) :25963-25969
[8]   Detection of the human organic anion transporters SLUM (OATP2) and SLC21A8 (OATP8) in liver and hepatocellular carcinoma [J].
Cui, YH ;
König, J ;
Nies, AT ;
Pfannschmidt, M ;
Hergt, M ;
Franke, WW ;
Alt, W ;
Moll, R ;
Keppler, D .
LABORATORY INVESTIGATION, 2003, 83 (04) :527-538
[9]   Drug transport proteins in the liver [J].
Faber, KN ;
Müller, M ;
Jansen, PLM .
ADVANCED DRUG DELIVERY REVIEWS, 2003, 55 (01) :107-124
[10]   Physiological, pharmacological and clinical features of the multidrug resistance protein 2 [J].
Fardel, O ;
Jigorel, E ;
Le Vee, M ;
Payen, L .
BIOMEDICINE & PHARMACOTHERAPY, 2005, 59 (03) :104-114